ProQR spotlights the most encouraging results from a mixed snapshot of efficacy for cystic fibrosis
Execs at ProQR Therapeutics $PRQR are doing their level best this afternoon to accentuate the positive in their early snapshot of the impact its lead RNA therapy has on cystic fibrosis. The big question is whether they can get investors to look past a slate of failed p-values in the Phase Ib — as well as the implications of some heavyweight competition — as they line up regulatory insights for the next big clinical development step.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.